PHVS vs PLRZ

Pharvaris N.V. vs Polyrizon Ltd. — Valuation Comparison 2026

PHVS

Biotechnology
Pharvaris N.V.
Quality
3.9
out of 10
Value Trap
6
SAFE
Price
$29.86
Last close
Models
7/13
Active
VS

PLRZ

Biotechnology
Polyrizon Ltd.
Quality
2.3
out of 10
Value Trap
Price
$16.50
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType PHVS Fair ValuePHVS Upside PLRZ Fair ValuePLRZ Upside
Bayesian DCF Intrinsic $10.81 -63.8% $4.37 -73.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $4.54 -84.8% $6.53 -60.4%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $18.67 +13.1%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for PHVS vs PLRZ — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PHVS vs PLRZ — Which Stock Is More Undervalued?

PHVS scores higher with a 3.9/10 quality rating vs PLRZ's 2.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Pharvaris N.V. (PHVS) and Polyrizon Ltd. (PLRZ) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PHVS currently trades at $29.86 with a QOC of 3.9/10, while PLRZ trades at $16.50 with a QOC of 2.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).